Mycoplasma Detection System Market Size, Trends and Insights By Product (Instruments, Kits & Reagents, PCR Assays, Nucleic Acid Detection Kits, Stains, Elimination Kits, Standards & Controls, Others, Services), By Technology (PCR, ELISA, Direct Assay, Indirect Assay, Microbial Culture Techniques, Enzymatic Methods), By Application (Cell Line Testing, Virus Testing, End of Production Cells Testing, Others), By End-use (Academic Research Institutes, Cell Banks, Contract Research Organizations, Pharmaceutical & Biotechnology Companies, Others), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2024–2033
Report Snapshot
| Study Period: | 2024-2033 |
| Fastest Growing Market: | Asia-Pacific |
| Largest Market: | Europe |
Major Players
- InvivoGen
- Lonza
- Thermo Fisher Scientific Inc.
- Eurofins Scientific
- Bionique Testing Laboratories LLC
- ATCC
- Others
Reports Description
As per the current market research conducted by the CMI Research Team, the global Mycoplasma Detection System Market is expected to record a CAGR of 12% from 2023 to 2032. In 2022, the market size is projected to reach a valuation of USD 0.8 Billion. By 2032, the valuation is anticipated to reach USD 2.3 Billion.
Mycoplasma testing involves the process of identifying and detecting mycoplasma bacteria present in biological samples, including but not limited to cell cultures and clinical specimens. Mycoplasma, a group of diminutive bacteria characterized by the absence of a cell wall, exhibits resilience in diverse environments, including laboratory cell cultures.
Their propensity to contaminate these cultures can result in cell behavior and characteristic alterations, subsequently impacting the accuracy and reliability of research outcomes. Thus, mycoplasma testing assumes a critical role in cell culture research and the production of biological products, serving as a vital safeguard to ensure the integrity and purity of these cultures while effectively mitigating the risk of contamination.
Mycoplasma Detection System Market – Significant Growth Factors
The mycoplasma testing market is witnessing growth and innovation within the diagnostic industry. This growth is primarily driven by the escalating incidences of mycoplasma contaminations in the pharmaceutical and biotechnology sectors, presenting a significant opportunity for the expansion of the mycoplasma testing market.
A key contributing factor to this market growth is the surging demand for mycoplasma testing products, particularly from the biopharmaceutical industry. The biopharmaceutical sector is experiencing rapid expansion, and the production of biopharmaceuticals necessitates stringent quality control measures, among which mycoplasma testing holds paramount importance.
Consequently, there is a heightened demand for mycoplasma testing products and services, fueled by increased research activities within the biotechnology and biopharmaceutical domains. This trend underscores the pivotal role of mycoplasma testing in ensuring product purity and quality control within these industries.
The mycoplasma testing market is experiencing growth, thanks to notable technological advancements that have led to the development of faster and more precise mycoplasma testing methods and instruments. These innovations are contributing to the expansion of the market’s share.
For instance, Minerva Biolabs GmbH offers the VenorGeM Advance Kit, a highly sensitive and specific solution designed for the detection of mycoplasma contamination in various biological matrices, including cell cultures. Similarly, Sartorius AG provides the Microsart Mycoplasma qPCR Detection Assay Kits, which are rapid and compliant with industry guidelines for mycoplasma detection. These kits are recognized for their exceptional specificity and sensitivity, delivering rapid results that are invaluable in pharmaceutical quality control processes.
Furthermore, the growing demand for biologics and biosimilars is a significant driver of market expansion. Mycoplasma contamination poses a potential threat during the manufacturing of biologics and biosimilars, compromising product quality, efficacy, and patient safety. As the demand for biologics and biosimilars continues to surge, the necessity for effective mycoplasma testing solutions is on the rise, further bolstering market growth.
For example, as of April 2021, the Food and Drug Administration (FDA) has greenlit 29 biosimilars, with 20 of them already launched in the U.S. Moreover, an uptick in promotional efforts by manufacturers and heightened awareness regarding mycoplasma testing are anticipated to stimulate adoption in the near future.
Conversely, the mycoplasma testing market faces challenges stemming from the elevated expenses associated with mycoplasma testing kits and instruments, as well as the scarcity of proficient laboratory technicians. These factors collectively impede the adoption of mycoplasma testing products and exert a dampening effect on market expansion.
For instance, consider SouthernBiotech’s Mycoplasma Detection Kit, which commands a price range of approximately $200 to $250. Moreover, when it comes to mycoplasma testing for patient specimens such as tissue, blood, and other bodily secretions, the costs can reach around $210. Consequently, the substantial costs associated with mycoplasma testing products, attributable to their specialized kits and reagents, are poised to hinder market growth.
Mycoplasma Detection System Market – Mergers and Acquisitions
- Thermo Fisher Scientific Acquires Becton, Dickinson and Company (BD): In March 2017, Thermo Fisher Scientific, a leading life sciences company, acquired the assets of BD’s Advanced Bioprocessing business. This strategic move bolstered Thermo Fisher’s capabilities in the field of bioproduction, including mycoplasma detection technologies.
- Lonza Group Acquires Vivante GMP Solutions: In October 2020, Lonza Group, a global leader in life sciences, completed the acquisition of Vivante GMP Solutions, a provider of mycoplasma testing services and technology. This acquisition strengthened Lonza’s offerings in the field of cell and gene therapy manufacturing.
- PromoCell Acquires CellSystems Biotechnologie AG: In November 2018, PromoCell, a leading manufacturer of cell culture products, acquired CellSystems Biotechnologie AG. This acquisition expanded PromoCell’s portfolio of mycoplasma detection and elimination products, supporting cell culture quality control.
- Merck KGaA Acquires Sigma-Aldrich: In 2015, Merck KGaA acquired Sigma-Aldrich, a major provider of life science and technology products. This acquisition expanded Merck’s portfolio of research tools, including mycoplasma detection and prevention products.
- Eurofins Scientific Acquires QTA Testing: In August 2021, Eurofins Scientific, a global leader in laboratory testing services, acquired QTA Testing, a provider of mycoplasma testing and biopharmaceutical services. This acquisition enhanced Eurofins’ capabilities in biopharmaceutical testing.
- Minerva Biolabs Acquires R-Biopharm: In June 2021, Minerva Biolabs, a provider of mycoplasma testing solutions, acquired R-Biopharm AG’s Cell Culture Diagnostics business. This acquisition expanded Minerva Biolabs’ product portfolio for cell culture quality control.
- SGS Acquires M-Scan: In 2019, SGS, a global leader in inspection, verification, testing, and certification services, acquired M-Scan, a contract research organization specializing in mycoplasma testing services for the biopharmaceutical industry. This acquisition strengthened SGS’s offerings in biopharmaceutical testing.
COMPARATIVE ANALYSIS OF THE RELATED MARKET
| Mycoplasma Detection System Market | Mental Health Technology Market | 3D Printed Medical Implant Market |
| CAGR 12% (Approx) | CAGR 16% (Approx) | CAGR 19.2% (Approx) |
| USD 2.3 Billion by 2032 | USD 18.9 Billion by 2032 | USD 9,099.9 Million by 2032 |
Mycoplasma Detection System Market – Significant Threats
- High Cost of Testing: The cost associated with mycoplasma detection tests, especially when conducted on a large scale, can be substantial. This expense may discourage some research laboratories and biopharmaceutical companies from conducting routine mycoplasma testing.
- Technical Expertise: Effective mycoplasma testing requires technical expertise and specialized equipment. The shortage of skilled laboratory technicians with expertise in mycoplasma detection methods can hinder the adoption of these tests.
- Sample Contamination: Cross-contamination between samples during mycoplasma testing can lead to false-positive results. Ensuring proper laboratory protocols and hygiene is essential to mitigate this risk.
- False-Negative Results: Mycoplasma bacteria are not always present in uniform concentrations in biological samples. As a result, some mycoplasma tests may yield false-negative results, leading to undetected contamination.
- Rapid Mutation: Mycoplasma bacteria have a propensity for rapid mutation, which can result in changes in their genetic makeup and antigenic properties. This genetic diversity can make it challenging to detect all mycoplasma strains using standard tests.
- Market Fragmentation: The mycoplasma detection market is characterized by a multitude of testing methods and technologies. This fragmentation can make it challenging for end-users to select the most suitable and reliable testing approach.
- Regulatory Compliance: Meeting regulatory requirements for mycoplasma testing, especially in the biopharmaceutical industry, can be demanding. Companies must ensure their testing methods and equipment comply with industry-specific regulations.
- Emerging Technologies: The continuous development of new and advanced technologies for mycoplasma detection requires companies to stay updated and adapt to evolving market trends and customer preferences.
- Global Health Events: Unforeseen global health events, such as pandemics or natural disasters, can disrupt supply chains, impact laboratory operations, and affect the availability of mycoplasma testing products.
- Data Privacy and Security: As mycoplasma testing becomes increasingly digitized and connected, concerns about data privacy and security may arise. Ensuring the confidentiality and integrity of sensitive testing data is critical.
- Market Competition: Intense competition among companies offering mycoplasma testing products and services can lead to price wars and decreased profit margins.
Report Scope
| Feature of the Report | Details |
| Market Size in 2023 | USD 0.9 Billion |
| Projected Market Size in 2032 | USD 2.3 Billion |
| Market Size in 2022 | USD 0.8 Billion |
| CAGR Growth Rate | 12% CAGR |
| Base Year | 2023 |
| Forecast Period | 2024-2033 |
| Key Segment | By Product, Technology , Application, End-use and Region |
| Report Coverage | Revenue Estimation and Forecast, Company Profile, Competitive Landscape, Growth Factors and Recent Trends |
| Regional Scope | North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America |
| Buying Options | Request tailored purchasing options to fulfil your requirements for research. |
Category-Wise Insights
By Product Type:
In 2022, the segment dedicated to kits and reagents emerged as the top revenue generator, commanding a significant share of 51.63% within the mycoplasma detection market. This dominance can be attributed to the robust demand for these products in mycoplasma detection procedures, coupled with their relatively higher cost.
Market players have proactively developed specialized mycoplasma detection kits tailored to the specific requirements of researchers and biopharmaceutical manufacturers. This strategic focus on creating tailored solutions has driven substantial growth within this segment.
Furthermore, the mycoplasma detection landscape is witnessing an increasing availability of automated equipment designed for efficient mycoplasma detection. Consequently, the instruments segment is poised to experience noteworthy growth throughout the projected period.
By Technology:
The PCR (Polymerase Chain Reaction) segment asserted its dominance in the mycoplasma testing market, capturing a substantial revenue share of 33.38% in 2022. Moreover, it stands out as the fastest-growing segment throughout the projected period.
PCR is an approach that allows for the isolation of other contaminating DNA elements while simultaneously facilitating the detection of a wide range of mycoplasma species. This method offers highly efficient and specific test results, rendering it particularly advantageous. One of the key benefits offered by PCR technology is its user-friendliness and rapid detection capabilities.
For instance, Merck KGaA has introduced the LookOut Mycoplasma PCR Detection Kit, simplifying the process of identifying contamination with Ureaplasma, Mycoplasma, and Acholeplasma in cell-derived biologicals and cell culture lines. This exemplifies the convenience and efficiency that PCR-based methods bring to mycoplasma detection.
Mycoplasma Detection Market – Regional Analysis
- North America: North America, particularly the United States and Canada, boasts a significant share in the mycoplasma detection market. This prominence is attributed to a robust biotechnology and pharmaceutical industry, extensive research and development activities, and stringent regulatory standards. Additionally, the region’s focus on biopharmaceutical production fuels the demand for mycoplasma testing to ensure product quality and safety.
- Europe: Europe is another prominent player in the mycoplasma detection market, with countries such as Germany, the United Kingdom, and France leading the way. The region benefits from a well-established healthcare infrastructure and a thriving biopharmaceutical sector. The stringent regulations regarding the safety and quality of biologics contribute to the adoption of mycoplasma testing solutions.
- Asia-Pacific: The Asia-Pacific region, including countries like China, Japan, and India, is witnessing substantial growth in mycoplasma detection. The increasing presence of biopharmaceutical companies, research organizations, and contract manufacturing facilities drives demand. Additionally, government initiatives to support biotechnology research and development further bolster market growth.
- Latin America: Latin America is emerging as a promising market for mycoplasma detection, mainly due to the growth of the biopharmaceutical industry and rising research activities. Brazil and Mexico are key contributors to the regional market.
List of the prominent players in the Mycoplasma Detection System Market:
- InvivoGen
- Lonza
- Thermo Fisher Scientific Inc.
- Eurofins Scientific
- Bionique Testing Laboratories LLC
- ATCC
- Norgen Biotek Corp.
- Bio-Rad Laboratories Inc
- Hoffmann-La Roche Ltd.
- Charles River Laboratories
- Others
The Mycoplasma Detection System Market is segmented as follows:
By Product
- Instruments
- Kits & Reagents
- PCR Assays
- Nucleic Acid Detection Kits
- Stains
- Elimination Kits
- Standards & Controls
- Others
- Services
By Technology
- PCR
- ELISA
- Direct Assay
- Indirect Assay
- Microbial Culture Techniques
- Enzymatic Methods
By Application
- Cell Line Testing
- Virus Testing
- End of Production Cells Testing
- Others
By End-use
- Academic Research Institutes
- Cell Banks
- Contract Research Organizations
- Pharmaceutical & Biotechnology Companies
- Others
Regional Coverage:
North America
- U.S.
- Canada
- Mexico
- Rest of North America
Europe
- Germany
- France
- U.K.
- Italy
- Spain
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- New Zealand
- Australia
- South Korea
- Rest of Asia Pacific
The Middle East & Africa
- Saudi Arabia
- UAE
- Egypt
- Kuwait
- South Africa
- Rest of the Middle East & Africa
Latin America
- Brazil
- Argentina
- Rest of Latin America
Table of Contents
- Chapter 1. Preface
- 1.1 Report Description and Scope
- 1.2 Research scope
- 1.3 Research methodology
- 1.3.1 Market Research Type
- 1.3.2 Market Research Methodology
- Chapter 2. Executive Summary
- 2.1 Global Mycoplasma Detection System Market, (2024 – 2033) (USD Billion)
- 2.2 Global Mycoplasma Detection System Market: snapshot
- Chapter 3. Global Mycoplasma Detection System Market – Industry Analysis
- 3.1 Mycoplasma Detection System Market: Market Dynamics
- 3.2 Market Drivers
- 3.2.1 Rising Awareness
- 3.2.2 Biopharmaceutical Industry Growth
- 3.2.3 Technological Advancements
- 3.2.4 Regulatory Compliance
- 3.2.5 Increasing Research Activities
- 3.2.6 Global Health Concerns
- 3.2.7 Market Competition
- 3.2.8 Cost-Effective Solutions
- 3.2.9 International Collaboration
- 3.2.10 Supply Chain Resilience.
- 3.3 Market Restraints
- 3.4 Market Opportunities
- 3.5 Market Challenges
- 3.6 Porter’s Five Forces Analysis
- 3.7 Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Product
- 3.7.2 Market Attractiveness Analysis By Technology
- 3.7.3 Market Attractiveness Analysis By Application
- 3.7.4 Market Attractiveness Analysis By End-use
- Chapter 4. Global Mycoplasma Detection System Market- Competitive Landscape
- 4.1 Company market share analysis
- 4.1.1 Global Mycoplasma Detection System Market: Company Market Share, 2022
- 4.2 Strategic development
- 4.2.1 Acquisitions & mergers
- 4.2.2 New Product launches
- 4.2.3 Agreements, partnerships, collaboration, and joint ventures
- 4.2.4 Research and development and Regional expansion
- 4.3 Price trend analysis
- 4.1 Company market share analysis
- Chapter 5. Global Mycoplasma Detection System Market – Product Analysis
- 5.1 Global Mycoplasma Detection System Market Overview: By Product
- 5.1.1 Global Mycoplasma Detection System Market Share, By Product, 2022 and – 2033
- 5.2 Instruments
- 5.2.1 Global Mycoplasma Detection System Market by Instruments, 2024 – 2033 (USD Billion)
- 5.3 Kits & Reagents
- 5.3.1 Global Mycoplasma Detection System Market by Kits & Reagents, 2024 – 2033 (USD Billion)
- 5.4 PCR Assays
- 5.4.1 Global Mycoplasma Detection System Market by PCR Assays, 2024 – 2033 (USD Billion)
- 5.5 Nucleic Acid Detection Kits
- 5.5.1 Global Mycoplasma Detection System Market by Nucleic Acid Detection Kits, 2024 – 2033 (USD Billion)
- 5.6 Stains
- 5.6.1 Global Mycoplasma Detection System Market by Stains, 2024 – 2033 (USD Billion)
- 5.7 Elimination Kits
- 5.7.1 Global Mycoplasma Detection System Market by Elimination Kits, 2024 – 2033 (USD Billion)
- 5.8 Standards & Controls
- 5.8.1 Global Mycoplasma Detection System Market by Standards & Controls, 2024 – 2033 (USD Billion)
- 5.9 Others
- 5.9.1 Global Mycoplasma Detection System Market by Others, 2024 – 2033 (USD Billion)
- 5.10 Services
- 5.10.1 Global Mycoplasma Detection System Market by Services, 2024 – 2033 (USD Billion)
- 5.1 Global Mycoplasma Detection System Market Overview: By Product
- Chapter 6. Global Mycoplasma Detection System Market – Technology Analysis
- 6.1 Global Mycoplasma Detection System Market Overview: By Technology
- 6.1.1 Global Mycoplasma Detection System Market Share, By Technology, 2022 and – 2033
- 6.2 PCR
- 6.2.1 Global Mycoplasma Detection System Market by PCR, 2024 – 2033 (USD Billion)
- 6.3 ELISA
- 6.3.1 Global Mycoplasma Detection System Market by ELISA, 2024 – 2033 (USD Billion)
- 6.4 Direct Assay
- 6.4.1 Global Mycoplasma Detection System Market by Direct Assay, 2024 – 2033 (USD Billion)
- 6.5 Indirect Assay
- 6.5.1 Global Mycoplasma Detection System Market by Indirect Assay, 2024 – 2033 (USD Billion)
- 6.6 Microbial Culture Techniques
- 6.6.1 Global Mycoplasma Detection System Market by Microbial Culture Techniques, 2024 – 2033 (USD Billion)
- 6.7 Enzymatic Methods
- 6.7.1 Global Mycoplasma Detection System Market by Enzymatic Methods, 2024 – 2033 (USD Billion)
- 6.1 Global Mycoplasma Detection System Market Overview: By Technology
- Chapter 7. Global Mycoplasma Detection System Market – Application Analysis
- 7.1 Global Mycoplasma Detection System Market Overview: By Application
- 7.1.1 Global Mycoplasma Detection System Market Share, By Application, 2022 and – 2033
- 7.2 Cell Line Testing
- 7.2.1 Global Mycoplasma Detection System Market by Cell Line Testing, 2024 – 2033 (USD Billion)
- 7.3 Virus Testing
- 7.3.1 Global Mycoplasma Detection System Market by Virus Testing, 2024 – 2033 (USD Billion)
- 7.4 End of Production Cells Testing
- 7.4.1 Global Mycoplasma Detection System Market by End of Production Cells Testing, 2024 – 2033 (USD Billion)
- 7.5 Others
- 7.5.1 Global Mycoplasma Detection System Market by Others, 2024 – 2033 (USD Billion)
- 7.1 Global Mycoplasma Detection System Market Overview: By Application
- Chapter 8. Global Mycoplasma Detection System Market – End-use Analysis
- 8.1 Global Mycoplasma Detection System Market Overview: By End-use
- 8.1.1 Global Mycoplasma Detection System Market Share, By End-use, 2022 and – 2033
- 8.2 Academic Research Institutes
- 8.2.1 Global Mycoplasma Detection System Market by Academic Research Institutes, 2024 – 2033 (USD Billion)
- 8.3 Cell Banks
- 8.3.1 Global Mycoplasma Detection System Market by Cell Banks, 2024 – 2033 (USD Billion)
- 8.4 Contract Research Organizations
- 8.4.1 Global Mycoplasma Detection System Market by Contract Research Organizations, 2024 – 2033 (USD Billion)
- 8.5 Pharmaceutical & Biotechnology Companies
- 8.5.1 Global Mycoplasma Detection System Market by Pharmaceutical & Biotechnology Companies, 2024 – 2033 (USD Billion)
- 8.6 Others
- 8.6.1 Global Mycoplasma Detection System Market by Others, 2024 – 2033 (USD Billion)
- 8.1 Global Mycoplasma Detection System Market Overview: By End-use
- Chapter 9. Mycoplasma Detections System Market – Regional Analysis
- 9.1 Global Mycoplasma Detections System Market Regional Overview
- 9.2 Global Mycoplasma Detections System Market Share, by Region, 2022 & – 2033 (USD Billion)
- 9.3. North America
- 9.3.1 North America Mycoplasma Detections System Market, 2024 – 2033 (USD Billion)
- 9.3.1.1 North America Mycoplasma Detections System Market, by Country, 2024 – 2033 (USD Billion)
- 9.3.1 North America Mycoplasma Detections System Market, 2024 – 2033 (USD Billion)
- 9.4 North America Mycoplasma Detections System Market, by Product, 2024 – 2033
- 9.4.1 North America Mycoplasma Detections System Market, by Product, 2024 – 2033 (USD Billion)
- 9.5 North America Mycoplasma Detections System Market, by Technology, 2024 – 2033
- 9.5.1 North America Mycoplasma Detections System Market, by Technology, 2024 – 2033 (USD Billion)
- 9.6 North America Mycoplasma Detections System Market, by Application, 2024 – 2033
- 9.6.1 North America Mycoplasma Detections System Market, by Application, 2024 – 2033 (USD Billion)
- 9.7 North America Mycoplasma Detections System Market, by End-use, 2024 – 2033
- 9.7.1 North America Mycoplasma Detections System Market, by End-use, 2024 – 2033 (USD Billion)
- 9.8. Europe
- 9.8.1 Europe Mycoplasma Detections System Market, 2024 – 2033 (USD Billion)
- 9.8.1.1 Europe Mycoplasma Detections System Market, by Country, 2024 – 2033 (USD Billion)
- 9.8.1 Europe Mycoplasma Detections System Market, 2024 – 2033 (USD Billion)
- 9.9 Europe Mycoplasma Detections System Market, by Product, 2024 – 2033
- 9.9.1 Europe Mycoplasma Detections System Market, by Product, 2024 – 2033 (USD Billion)
- 9.10 Europe Mycoplasma Detections System Market, by Technology, 2024 – 2033
- 9.10.1 Europe Mycoplasma Detections System Market, by Technology, 2024 – 2033 (USD Billion)
- 9.11 Europe Mycoplasma Detections System Market, by Application, 2024 – 2033
- 9.11.1 Europe Mycoplasma Detections System Market, by Application, 2024 – 2033 (USD Billion)
- 9.12 Europe Mycoplasma Detections System Market, by End-use, 2024 – 2033
- 9.12.1 Europe Mycoplasma Detections System Market, by End-use, 2024 – 2033 (USD Billion)
- 9.13. Asia Pacific
- 9.13.1 Asia Pacific Mycoplasma Detections System Market, 2024 – 2033 (USD Billion)
- 9.13.1.1 Asia Pacific Mycoplasma Detections System Market, by Country, 2024 – 2033 (USD Billion)
- 9.13.1 Asia Pacific Mycoplasma Detections System Market, 2024 – 2033 (USD Billion)
- 9.14 Asia Pacific Mycoplasma Detections System Market, by Product, 2024 – 2033
- 9.14.1 Asia Pacific Mycoplasma Detections System Market, by Product, 2024 – 2033 (USD Billion)
- 9.15 Asia Pacific Mycoplasma Detections System Market, by Technology, 2024 – 2033
- 9.15.1 Asia Pacific Mycoplasma Detections System Market, by Technology, 2024 – 2033 (USD Billion)
- 9.16 Asia Pacific Mycoplasma Detections System Market, by Application, 2024 – 2033
- 9.16.1 Asia Pacific Mycoplasma Detections System Market, by Application, 2024 – 2033 (USD Billion)
- 9.17 Asia Pacific Mycoplasma Detections System Market, by End-use, 2024 – 2033
- 9.17.1 Asia Pacific Mycoplasma Detections System Market, by End-use, 2024 – 2033 (USD Billion)
- 9.18. Latin America
- 9.18.1 Latin America Mycoplasma Detections System Market, 2024 – 2033 (USD Billion)
- 9.18.1.1 Latin America Mycoplasma Detections System Market, by Country, 2024 – 2033 (USD Billion)
- 9.18.1 Latin America Mycoplasma Detections System Market, 2024 – 2033 (USD Billion)
- 9.19 Latin America Mycoplasma Detections System Market, by Product, 2024 – 2033
- 9.19.1 Latin America Mycoplasma Detections System Market, by Product, 2024 – 2033 (USD Billion)
- 9.20 Latin America Mycoplasma Detections System Market, by Technology, 2024 – 2033
- 9.20.1 Latin America Mycoplasma Detections System Market, by Technology, 2024 – 2033 (USD Billion)
- 9.21 Latin America Mycoplasma Detections System Market, by Application, 2024 – 2033
- 9.21.1 Latin America Mycoplasma Detections System Market, by Application, 2024 – 2033 (USD Billion)
- 9.22 Latin America Mycoplasma Detections System Market, by End-use, 2024 – 2033
- 9.22.1 Latin America Mycoplasma Detections System Market, by End-use, 2024 – 2033 (USD Billion)
- 9.23. The Middle-East and Africa
- 9.23.1 The Middle-East and Africa Mycoplasma Detections System Market, 2024 – 2033 (USD Billion)
- 9.23.1.1 The Middle-East and Africa Mycoplasma Detections System Market, by Country, 2024 – 2033 (USD Billion)
- 9.23.1 The Middle-East and Africa Mycoplasma Detections System Market, 2024 – 2033 (USD Billion)
- 9.24 The Middle-East and Africa Mycoplasma Detections System Market, by Product, 2024 – 2033
- 9.24.1 The Middle-East and Africa Mycoplasma Detections System Market, by Product, 2024 – 2033 (USD Billion)
- 9.25 The Middle-East and Africa Mycoplasma Detections System Market, by Technology, 2024 – 2033
- 9.25.1 The Middle-East and Africa Mycoplasma Detections System Market, by Technology, 2024 – 2033 (USD Billion)
- 9.26 The Middle-East and Africa Mycoplasma Detections System Market, by Application, 2024 – 2033
- 9.26.1 The Middle-East and Africa Mycoplasma Detections System Market, by Application, 2024 – 2033 (USD Billion)
- 9.27 The Middle-East and Africa Mycoplasma Detections System Market, by End-use, 2024 – 2033
- 9.27.1 The Middle-East and Africa Mycoplasma Detections System Market, by End-use, 2024 – 2033 (USD Billion)
- Chapter 10. Company Profiles
- 10.1 InvivoGen
- 10.1.1 Overview
- 10.1.2 Financials
- 10.1.3 Product Portfolio
- 10.1.4 Business Strategy
- 10.1.5 Recent Developments
- 10.2 Lonza
- 10.2.1 Overview
- 10.2.2 Financials
- 10.2.3 Product Portfolio
- 10.2.4 Business Strategy
- 10.2.5 Recent Developments
- 10.3 Thermo Fisher Scientific Inc.
- 10.3.1 Overview
- 10.3.2 Financials
- 10.3.3 Product Portfolio
- 10.3.4 Business Strategy
- 10.3.5 Recent Developments
- 10.4 Eurofins Scientific
- 10.4.1 Overview
- 10.4.2 Financials
- 10.4.3 Product Portfolio
- 10.4.4 Business Strategy
- 10.4.5 Recent Developments
- 10.5 Bionique Testing Laboratories LLC
- 10.5.1 Overview
- 10.5.2 Financials
- 10.5.3 Product Portfolio
- 10.5.4 Business Strategy
- 10.5.5 Recent Developments
- 10.6 ATCC
- 10.6.1 Overview
- 10.6.2 Financials
- 10.6.3 Product Portfolio
- 10.6.4 Business Strategy
- 10.6.5 Recent Developments
- 10.7 Norgen Biotek Corp.
- 10.7.1 Overview
- 10.7.2 Financials
- 10.7.3 Product Portfolio
- 10.7.4 Business Strategy
- 10.7.5 Recent Developments
- 10.8 Bio-Rad Laboratories
- 10.8.1 Overview
- 10.8.2 Financials
- 10.8.3 Product Portfolio
- 10.8.4 Business Strategy
- 10.8.5 Recent Developments
- 10.9 Charles River Laboratories
- 10.9.1 Overview
- 10.9.2 Financials
- 10.9.3 Product Portfolio
- 10.9.4 Business Strategy
- 10.9.5 Recent Developments
- 10.10 F. Hoffmann-La Roche Ltd.
- 10.10.1 Overview
- 10.10.2 Financials
- 10.10.3 Product Portfolio
- 10.10.4 Business Strategy
- 10.10.5 Recent Developments
- 10.11 Others.
- 10.11.1 Overview
- 10.11.2 Financials
- 10.11.3 Product Portfolio
- 10.11.4 Business Strategy
- 10.11.5 Recent Developments
- 10.1 InvivoGen
List Of Figures
Figures No 1 to 42
List Of Tables
Tables No 1 to 102
Report Methodology
In order to get the most precise estimates and forecasts possible, Custom Market Insights applies a detailed and adaptive research methodology centered on reducing deviations. For segregating and assessing quantitative aspects of the market, the company uses a combination of top-down and bottom-up approaches. Furthermore, data triangulation, which examines the market from three different aspects, is a recurring theme in all of our research reports. The following are critical components of the methodology used in all of our studies:
Preliminary Data Mining
On a broad scale, raw market information is retrieved and compiled. Data is constantly screened to make sure that only substantiated and verified sources are taken into account. Furthermore, data is mined from a plethora of reports in our archive and also a number of reputed & reliable paid databases. To gain a detailed understanding of the business, it is necessary to know the entire product life cycle and to facilitate this, we gather data from different suppliers, distributors, and buyers.
Surveys, technological conferences, and trade magazines are used to identify technical issues and trends. Technical data is also gathered from the standpoint of intellectual property, with a focus on freedom of movement and white space. The dynamics of the industry in terms of drivers, restraints, and valuation trends are also gathered. As a result, the content created contains a diverse range of original data, which is then cross-validated and verified with published sources.
Statistical Model
Simulation models are used to generate our business estimates and forecasts. For each study, a one-of-a-kind model is created. Data gathered for market dynamics, the digital landscape, development services, and valuation patterns are fed into the prototype and analyzed concurrently. These factors are compared, and their effect over the projected timeline is quantified using correlation, regression, and statistical modeling. Market forecasting is accomplished through the use of a combination of economic techniques, technical analysis, industry experience, and domain knowledge.
Short-term forecasting is typically done with econometric models, while long-term forecasting is done with technological market models. These are based on a synthesis of the technological environment, legal frameworks, economic outlook, and business regulations. Bottom-up market evaluation is favored, with crucial regional markets reviewed as distinct entities and data integration to acquire worldwide estimates. This is essential for gaining a thorough knowledge of the industry and ensuring that errors are kept to a minimum.
Some of the variables taken into account for forecasting are as follows:
• Industry drivers and constraints, as well as their current and projected impact
• The raw material case, as well as supply-versus-price trends
• Current volume and projected volume growth through 2030
We allocate weights to these variables and use weighted average analysis to determine the estimated market growth rate.
Primary Validation
This is the final step in our report’s estimating and forecasting process. Extensive primary interviews are carried out, both in-person and over the phone, to validate our findings and the assumptions that led to them.
Leading companies from across the supply chain, including suppliers, technology companies, subject matter experts, and buyers, use techniques like interviewing to ensure a comprehensive and non-biased overview of the business. These interviews are conducted all over the world, with the help of local staff and translators, to overcome language barriers.
Primary interviews not only aid with data validation, but also offer additional important insight into the industry, existing business scenario, and future projections, thereby improving the quality of our reports.
All of our estimates and forecasts are validated through extensive research work with key industry participants (KIPs), which typically include:
• Market leaders
• Suppliers of raw materials
• Suppliers of raw materials
• Buyers.
The following are the primary research objectives:
• To ensure the accuracy and acceptability of our data.
• Gaining an understanding of the current market and future projections.
Data Collection Matrix
| Perspective | Primary research | Secondary research |
| Supply-side |
|
|
| Demand-side |
|
|
Market Analysis Matrix
| Qualitative analysis | Quantitative analysis |
|
|
Prominent Player
- InvivoGen
- Lonza
- Thermo Fisher Scientific Inc.
- Eurofins Scientific
- Bionique Testing Laboratories LLC
- ATCC
- Norgen Biotek Corp.
- Bio-Rad Laboratories Inc
- Hoffmann-La Roche Ltd.
- Charles River Laboratories
- Others
FAQs
The key factors driving the Market are Rising Awareness, Biopharmaceutical Industry Growth, Technological Advancements, Regulatory Compliance, Increasing Research Activities, Global Health Concerns, Market Competition, Cost-Effective Solutions, International Collaboration And Supply Chain Resilience.
The “Product” category dominated the market in 2022.
The key players in the market are InvivoGen, Lonza, Thermo Fisher Scientific Inc., Eurofins Scientific, Bionique Testing Laboratories LLC, ATCC, Norgen Biotek Corp., Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche Ltd., Charles River Laboratories, Others.
“Asia Pacific” had the largest share in the Mycoplasma Detection System Market.
The global market is projected to grow at a CAGR of 12% during the forecast period, 2023-2032.
The Mycoplasma Detection System Market size was valued at USD 0.8 Billion in 2022.